MedinCell S.A. (EPA:MEDCL)
France flag France · Delayed Price · Currency is EUR
15.57
-0.33 (-2.08%)
Jul 22, 2025, 1:44 PM CET

MedinCell Company Description

MedinCell S.A., a pharmaceutical company, develops long acting injectables in various therapeutic areas in France.

It develops solutions based on BEPO, a long-acting injectable technology; and offers UZEDY (mdc-IRM) for the treatment of schizophrenia in adults.

The company’s products in development include mdc-CWM, a sustained-release formulation of celecoxib in Phase III trials for use in the treatment of reduction of postoperative pain and inflammation; and mdc-TJK, a subcutaneous injection that is in Phase III clinical trials for use in the treatment of schizophrenia.

Its product candidates in preclinical trials include mdc-WWM for contraception; and mdc-STM for malaria.

MedinCell S.A. was incorporated in 2003 and is headquartered in Jacou, France.

MedinCell S.A.
MedinCell logo
CountryFrance
Founded2003
IndustryBiotechnology
SectorHealthcare
Employees140
CEOChristophe Douat

Contact Details

Address:
3 rue des FrEres LumiEre
Jacou, 34830
France
Phone33 4 67 02 13 67
Websitemedincell.com

Stock Details

Ticker SymbolMEDCL
ExchangeEuronext Paris
Fiscal YearApril - March
Reporting CurrencyEUR
ISIN NumberFR0004065605
SIC Code2834

Key Executives

NamePosition
Christophe DouatChief Executive Officer and Director
Franck PouzacheChief People Officer and Member of the Management Board
Stephane PosticChief Financial Officer
Philippe MoyenChief Operating Officer
Dr. Grace Kim Ph.D.Head of US Financial Strategy and Investor Relations
Julie AlimiGeneral Counsel and Chief Corporate Development Officer
David HeuzeHead of Corporate and Financial Communications and ESG
Adolfo Lopez-NoriegaHead of Research and Development
Sebastien EnaultChief Business Officer
Quiterie De BeauregardHead of Global Health Development